Melphalan flufenamide (Pepaxti®). HTA ID: 23067

Assessment Status Rapid Review Complete
HTA ID 23067
Drug Melphalan flufenamide
Brand Pepaxti®
Indication Melphalan flufenamide (Pepaxti®) is indicated in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least three years from transplantation.
Assessment Process
Rapid review commissioned 09/11/2023
Rapid review completed 15/12/2023
Rapid review outcome A full HTA is not recommended. On the basis of current evidence, the NCPE recommends that melphalan flufenamide in combination with dexamethasone not be considered for reimbursement *.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.